Answers are grounded in this paper and cite their sources.
This cross-sectional cost analysis uses data from the 2018 Health and Retirement Study to estimate the potential future Medicare spending and beneficiary costs for lecanemab.
No takes yet. Share an insight, caveat, or question.
Arbanas et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: